Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT.

Oncotarget. 2014 Jan 15;5(1):258-63.

2.

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG, Barata JT.

Blood. 2010 Oct 14;116(15):2724-31. doi: 10.1182/blood-2010-04-277947. Epub 2010 Jul 21.

3.

On CK2 regulation of chronic lymphocytic leukemia cell viability.

Martins LR, Lúcio P, Silva MC, Gameiro P, Silva MG, Barata JT.

Mol Cell Biochem. 2011 Oct;356(1-2):51-5. doi: 10.1007/s11010-011-0947-6. Epub 2011 Jul 13.

PMID:
21750986
4.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25.

PMID:
18575815
5.

CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.

Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF, Farina HG.

Lung Cancer. 2017 May;107:14-21. doi: 10.1016/j.lungcan.2016.05.026. Epub 2016 Jun 1.

PMID:
27319334
6.

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.

Gomes AM, Soares MV, Ribeiro P, Caldas J, Póvoa V, Martins LR, Melão A, Serra-Caetano A, de Sousa AB, Lacerda JF, Barata JT.

Haematologica. 2014 Jun;99(6):1062-8. doi: 10.3324/haematol.2013.096438. Epub 2014 Feb 21.

7.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC.

Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21.

8.

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.

McCaig AM, Cosimo E, Leach MT, Michie AM.

Br J Haematol. 2011 Apr;153(2):199-211. doi: 10.1111/j.1365-2141.2010.08507.x. Epub 2011 Feb 24.

PMID:
21352196
9.

Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.

Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, Pandiella A, Terol MJ, García-Marco JA, García-Pardo A.

Clin Cancer Res. 2010 Sep 1;16(17):4382-91. doi: 10.1158/1078-0432.CCR-10-0072. Epub 2010 Jun 9.

10.

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M, Gaiger A, Zielinski C, Schwarzmeier JD, Jaeger U.

Blood. 2010 Oct 7;116(14):2513-21. doi: 10.1182/blood-2009-10-248054. Epub 2010 Jun 24.

11.

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, Schjerven H, Muschen M, Payne KJ, Dovat S.

Blood. 2015 Oct 8;126(15):1813-22. doi: 10.1182/blood-2015-06-651505. Epub 2015 Jul 28.

12.

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7.

PMID:
21735096
13.

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G.

Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.

14.

The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.

Barata JT.

Adv Enzyme Regul. 2011;51(1):37-49. doi: 10.1016/j.advenzreg.2010.09.012. Epub 2010 Oct 28. Review.

PMID:
21035501
15.

Regulation of taurine homeostasis by protein kinase CK2 in mouse fibroblasts.

Hansen DB, Guerra B, Jacobsen JH, Lambert IH.

Amino Acids. 2011 Apr;40(4):1091-106. doi: 10.1007/s00726-010-0732-y. Epub 2010 Sep 9.

PMID:
20827495
16.

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.

Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Mol Cancer Ther. 2009 May;8(5):1189-96. doi: 10.1158/1535-7163.MCT-08-1056. Epub 2009 May 5.

17.

Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.

Hung MS, Xu Z, Lin YC, Mao JH, Yang CT, Chang PJ, Jablons DM, You L.

BMC Cancer. 2009 May 6;9:135. doi: 10.1186/1471-2407-9-135.

18.

AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.

Escobar-Díaz E, López-Martín EM, Hernández del Cerro M, Puig-Kroger A, Soto-Cerrato V, Montaner B, Giralt E, García-Marco JA, Pérez-Tomás R, Garcia-Pardo A.

Leukemia. 2005 Apr;19(4):572-9.

PMID:
15744353
19.

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC.

Blood. 2014 Aug 28;124(9):1481-91. doi: 10.1182/blood-2014-05-574830. Epub 2014 Jul 7.

20.

The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

Paesler J, Gehrke I, Gandhirajan RK, Filipovich A, Hertweck M, Erdfelder F, Uhrmacher S, Poll-Wolbeck SJ, Hallek M, Kreuzer KA.

Clin Cancer Res. 2010 Jul 1;16(13):3390-8. doi: 10.1158/1078-0432.CCR-10-0232. Epub 2010 Jun 22.

Supplemental Content

Support Center